In vivo rat PK profiling in drug discovery: New challenges

Expert Opinion on Drug Discovery

Volumn 5, Issue 11, 2010, Pages 1031-1037

  Zonzini, Laura ^a,b   Bianchi, Federica ^b   Cesari, Nicola ^c   Sartori, Matteo ^b  

^a GSK   (Italy)

^b Aptuit Inc   (United States)

^c CHIESI FARMACEUTICI S P A   (Italy)

Author keywords

biophase; drug discovery; in vivo; PK; rat; screening

Indexed keywords

AREA UNDER THE CURVE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG QUALITY; DRUG SAFETY; DRUG SCREENING; IN VIVO STUDY; INTRAVENOUS DRUG ADMINISTRATION; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; RAT; REVIEW; RISK ASSESSMENT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; INJECTIONS, INTRAVENOUS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; RATS; TISSUE DISTRIBUTION;

EID: 77958589587     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.2010.509396     Document Type: Review

References (34)

1. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711-5
2. Kerns EH, Di L. Pharmaceutical profiling in drug discovery. DDT 2003;8:316-23
3. Ruiz-Garcia A, Bermejo M, Moss A, Casabo VG. Pharmacokinetics in drug discovery. J Pharm Sci 2008;97(2):654-90
4. Kola I. The state of innovation in drug development. Clin Pharmacol Ther 2008;83(2):227-30
5. Roberts SA. Drug metabolism and pharmacokinetics in drug discovery. Curr Opin Drug Discov Devel 2003;6:66-80
6. Summerfield S, Jeffrey P. Discovery DMPK: changing paradigms in the eighties, nineties and noughties. Expert Opin Drug Discov 2009;4(2):207-18
7. Korfmacher WA. Advances in the integration of drug metabolism into the lead optimization paradigm. Mini Rev Med Chem 2009;9:703-16
8. Braggio S, Montanari D, Rossi T, Ratti E. Drug efficiency: a new concept to guide lead optimization programs towards the selection of better clinical candidates. Expert Opin Drug Discov 2010;5(7):1-10
9. Lee EJD, Lean CB, Limenta LMG. Role of membrane transporters in the safety profile of drugs. Expert Opin Drug Metab Toxicol 2009;5(11):1369-83
10. Berman J, Halm K, Adkison K, Shaffer J. Simultaneous pharmacokinetic screening of a mixture of compounds in the dog using API LC/MS/MS analysis for increased throughput. J Med Chem 1997;40:827-9
11. Aherne GW, McDonald E, Workman P. Finding the needle in the haystack: why high-throughput screening is good for your health. Breast Cancer Res 2002;4:148-54
12. Watt AP, Morrison II, Evans DC. Approaches to higher-throughput pharmacokinetics (HTPK) in drug discovery. Drug Discov Today 2000;5:17-24
13. He K, Qian M, Wong H, et al. N-in-1 dosing pharmacokinetics in drug discovery: experience, theoretical and practical considerations. J Pharm Sci 2008;97(7):2568-80
14. Diehl KH, Hull R, Morton D, et al. A good practice guide to the administration of substances and removal of blood, including routes and volumes. J Appl Toxicol 2001;21:15-23
15. Timmerman A. Puncture of the tail vein as possible alternative for orbital puncture in the rat. Anim Technol 1992;43:167-72
16. Kuze J, Mutoh T, Takenaka T, et al. Separate evaluation of intestinal and hepatic metabolism of three benzodiazepines in rats with cannulated portal and jugular veins: comparison with the profile in non-cannulated mice. Xenobiotica 2009;39(11):871-80
17. Tabata K, Yamaoka K, Fukuyama T, Nakagawa T. Evaluation of intestinal absorption into the portal system in enterohepatic circulation by measuring the difference in portal-venous blood concentrations of diclofenac. Pharm Res 1995;12:880-3
18. Hoffman DJ, Seifert T, Borre A, Nellans HN. Method to estimate the rate and extent of intestinal absorption in conscious rat using an absorption probe and portal blood sampling. Pharm Res 1995;12:889-94
19. Murakami T, Nakanishi M, Yoshimori T, et al. Separate assessment of intestinal and hepatic first-pass effects using a rat model with double cannulation of the portal and jugular veins. Drug Metab Pharmacokinet 2003;18:252-60
20. Kanazu T, Okamura N, Yamaguchi Y, et al. Assessment of the hepatic and intestinal first-pass metabolism of midazolam in a CYP3A drug-drug interaction model rats. Xenobiotica 2005;35:305-17
21. Varma MVS, Khandavillis S, Ashokraj Y, et al. Biopharmaceutic classification system: a scientific framework for pharmacokinetic optimization in drug research. Curr Drug Metab 2004;5:375-88
22. Chao P, Uss AS, Cheng KC. Use of intrinsic clearance for prediction of human hepatic clearance. Expert Opin Drug Metab Toxicol 2010;6(2):189-98
23. Ploeger BA, Van der Graaf PH, Danhof M. Incorporating receptor theory in mechanism-based pharmacokinetics-pharmacodynamics (PK-PD) modeling. Drug Metab Pharmacokinet 2009;24(1):3-15
24. Reichel A. Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept. Chem Biodivers 2009;6:2030-49
25. De Boer AG, Van der Sandt ICJ, Gaillard PJ. The role of drug transporters at the blood-brain barrier. Annu Rev Pharmacol Toxicol 2003;43:629-56
26. Kalvass JC, Maurer TS. Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos 2002;23:327-38
27. Summerfield S, Jeffrey P. In vitro predictions of brain penetration - a case for free thinking? Expert Opin Drug Discov 2006;1(6):595-607
28. Jeffrey P, Summerfield S. Challenges for blood-brain barrier (BBB) screening. Xenobiotica 2007;37(10-11):1135-51
29. Cutler L, Howes C, Deeks NJ, et al. Development of a P-glycoprotein knockout model in rodents to define species differences in its functional effect at the blood-brain barrier. J Pharm Sci 2006;95(9):1944-53
30. Wallstab A, Koester M, Bohme M, Keppler D. Selective inhibition of MDR1 P-glycoprotein-mediated transport by the acridone carboxamide derivative GG918. Br J Cancer 1999;79:1053-60
31. Cooray HC, Blackmore CG, Maskell L, Barrand MA. Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport 2002;13:2059-63
32. Walker DK. The use of pharmacocokinetic and pharmacodynamic data in the assessment of drug safety in early drug development. Br J Clin Pharmacol 2004;58(6):601-8
33. Non-clinical guideline on drug-induced hepatotoxicity. EMEA. London: EMEA/CHMP/SWP/150115/2006, 2008. Available from: www.emea.europa.eu
34. Kramer JA, Sagartz JE, Morris DL. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Nat Rev Drug Discov 2007;6:636-49